LNWTC
AZN icon

Laird Norton Wetherby Trust Company’s AstraZeneca AZN Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.45M Sell
49,857
-774
-2% -$146K 0.18% 86
2026
Q1 		$9.99M Sell
50,631
-228
-0.4% -$44K 0.22% 71
2025
Q4 		$9.35M Buy
+50,859
New +$8.92M 0.19% 75

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Laird Norton Wetherby Trust Company's AZN Position: Q2 2026 in Review

Laird Norton Wetherby Trust Company reduced its AstraZeneca (AZN) stake by 1.5% in Q2 2026, selling an estimated $146K and leaving 49,857 shares worth $9.45M. The position accounts for 0.18% of the portfolio, ranked #86.

Laird Norton Wetherby Trust Company first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.99M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Laird Norton Wetherby Trust Company held 49,857 shares of AstraZeneca worth $9.45M as of Q2 2026.
  • Laird Norton Wetherby Trust Company sold 774 AstraZeneca shares in Q2 2026, an estimated $146K.
  • AstraZeneca made up 0.18% of Laird Norton Wetherby Trust Company's portfolio in Q2 2026, its #86 holding.
  • Laird Norton Wetherby Trust Company first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • Laird Norton Wetherby Trust Company's AstraZeneca position peaked at $9.99M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q2 2026, filed 14 Aug 2026.